Journals / Respiratory Case Reports / 2017 / Cilt: 6 - Sayı: 3

Administration of Thrombolytic Treatment for Massive Pulmonary Embolism in a Patient on Prasugrel

Prasugrel Kullanırken Trombolitik Tedavi Uygulanan Masif Pulmoner Emboli Olgusu

Pages
149–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The present case is important because thrombolytic treatment for a patient who is on prasugrel has not been reported in the literature previously, and it illustrates that such therapy can be administered safely, though prasugrel has been associated with an increased rate of bleeding complications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 55-year-old female patient was admitted to emergency service for hypotension and syncope.
📊
Key Findings & Data:The patient was under dual antiplatelet therapy, aspirin, and prasugrel for coronary artery disease.
💡
Conclusion & Impact:The present case is important because thrombolytic treatment for a patient who is on prasugrel has not been reported in the literature previously, and it illustrates that such therapy can be administered safely, though prasugrel has been associated with an increased rate of bleeding complications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 55-year-old female patient was admitted to emergency service for hypotension and syncope. The patient was under dual antiplatelet therapy, aspirin, and prasugrel for coronary artery disease. Echocardiography revealed dilated right heart chambers as well as paradoxical septal motion, suggesting a diagnosis of pulmonary embolism. Thorax computerized tomography with contrast enhancement was performed and revealed thrombi in both main pulmonary arteries and their branches. Thrombolytic treatment was provided. There were no bleeding complications, and patient was discharged from the hospital on the seventh day, taking warfarin, clopidogrel, and aspirin. The present case is important because thrombolytic treatment for a patient who is on prasugrel has not been reported in the literature previously, and it illustrates that such therapy can be administered safely, though prasugrel has been associated with an increased rate of bleeding complications.

Özet

Elli beş yaşında, koroner arter hastalığı nedeni ile prasugrel ve asetilsalisilik asit kullanmakta olan kadın hasta, senkop ve hipotansiyon ile acile servise getirildi. Ekokardiyografide paradoks septum ve sağ ventrikülde genişleme saptanan, kontrastlı bilgisayarlı toraks tomografisinde bilateral ana pulmoner arterlerde ve dallarında yaygın trombüs görülen hastaya rt-PA uygulandı. Trombolitik bitiminde heparinize edilen hastanın tedavisine yirmi dördüncü saatte warfarin eklendi. Kanama komplikasyonu gelişmeyen hasta yedinci günde warfarin, klopidogrel, asetilsalisilikasit tedavileri altında taburcu edildi. Bu olgu, yeni kuşak antitrombotik olan presugrelin kanama riskinin yüksek olması, bu ilaç ile birlikte daha önce trombolitik kullanımının bildirilmemiş olması, sonuçta kanama komplikasyonu gelişmeden hastanın takip edilmesi açısından önemlidir.

🔖

Cite This Article

BAHA, A., BAHA, R. M., YILDIZ, İ. (2017). Administration of Thrombolytic Treatment for Massive Pulmonary Embolism in a Patient on Prasugrel. Respiratory Case Reports, Cilt: 6 - Sayı: 3, 149–152. https://ajindex.com/articles/302555

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975
  2. [CrossRef] 2. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999
  3. [CrossRef] 3. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997
  4. [CrossRef] 4. Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary embolism. JAMA 1976
  5. [CrossRef] 5. Torbicki A, Galie N, Covezzoli A, Rossi E, De Rosa M, Goldhaber SZ. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol 2003
  6. [CrossRef] 6. Türk Toraks Derneği Pulmoner Tromboemboli Tanı ve Tedavi Uzlaşı Raporu 2015. 7. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008
  7. [CrossRef] 8. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007
  8. [CrossRef] 9. Thrombosis Canada. Canadian Cardiovascular Society Antiplatelet Guidelines. 2013.